Opendata, web and dolomites

3DLT SIGNED

3D Living Tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DLT project word cloud

Explore the words cloud of the 3DLT project. It provides you a very rough idea of what is the project "3DLT" about.

trials    molecules    business    estimating    tests    drug    companies    corresponding    printing    animal    oncological    2019    develops    pharma    acquire    remaining    economic    clinical    cell    commercialization    price    connect    satisfy    strictly    deeply    unreliable    once    safety    markets    3dln    revenue    building    lymph    cancer    asymp    respect    ematik    feasibility       printed    expenditures    edge    jan    contrary    40mln    cutting    spends    composition    prometheus    ones    efficient    undertaking    fails    ink    living    performed    asap    times    node    pharmacological    immunotherapies    framework    opportunity    regenerative    commercial    ip    care    cells    compartmentalization    tissues    96    entire    human    preclinical    customers    yearn    1st    2bln    immuneonco    predictive    strategy    requests    reduce    alive    3d    drugs    5bln    industrial    bioprinting    proprietary    cosmetic    rate    mln    vitro    company    forecast    connecting    share    resolution    excluding    uncomplete    equal    time    medicine    structure    expenditure    data    market    wounds   

Project "3DLT" data sheet

The following table provides information about the project.

Coordinator
PROMETHEUS S.R.L. 

Organization address
address: VIA TRENTO 30
city: PARMA
postcode: 43122
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.prometheus3d.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROMETHEUS S.R.L. IT (PARMA) coordinator 50˙000.00

Map

 Project objective

Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More